Biopoin Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Biopoin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by the rising use of biologics, increasing demand for vaccines, a growing focus on rare diseases, expanding globalization, and improved access to healthcare.

In the forecast period, growth is expected to result from an increased emphasis on personalized medicine, a stronger focus on sustainability, the rising prevalence of chronic diseases, greater adoption of biosimilars, and growing demand for cell and gene therapies. Key trends anticipated during this period include advancements in cell-free biomanufacturing, decentralization of clinical trials, the development of oral biologics, the integration of blockchain technology for drug traceability, and progress in mRNA therapeutics.

The rising incidence of chronic kidney disease is expected to drive the growth of the biopoin market in the future. Chronic kidney disease (CKD) is a long-term disorder marked by the gradual decline of kidney function, resulting in the kidneys' reduced ability to filter waste and excess fluids from the blood effectively. The increasing rates of diabetes, hypertension, and poor dietary habits are the primary contributors to the prevalence of CKD. In CKD, lower erythropoietin production causes anemia, leading to fatigue and weakness. Biopoin, which contains epoetin theta, stimulates red blood cell production, raising hemoglobin levels and improving quality of life. For example, a report published in October 2024 by the National Health Service (NHS), a UK-based government agency, stated that the incidence and severity of chronic kidney disease increase with age, with nearly 50% of adults aged 75 and above affected by stages 1 to 5, including more than a third in the more severe stages 3 to 5. Additionally, a report from Oxford Academic in June 2023 projected that the number of individuals with CKD in the UK would increase by 4% from 2022 to 2032, rising from 8.27 million to 8.61 million. As a result, the growing prevalence of chronic kidney disease is fueling the expansion of the biopoin market.

The growing incidence of anemia is expected to drive the growth of the biopoin market. Anemia is a condition where there is a shortage of red blood cells or hemoglobin in the blood, reducing the ability to carry oxygen to body tissues. The rise in anemia cases is largely due to poor nutrition, lack of access to healthcare, chronic illnesses, and socioeconomic disparities. Biopoin serves as an iron supplement that restores iron levels, increasing hemoglobin production and enhancing oxygen transport in the blood. It also promotes red blood cell production, helping prevent anemia symptoms. For example, a report released in April 2024 by the Centers for Disease Control and Prevention (CDC), a US-based national health agency, revealed that there were 2.8 million doctor visits for anemia as the main diagnosis, with 6,021 deaths, leading to a mortality rate of 1.8 deaths per 100,000 people. Therefore, the rising prevalence of anemia is contributing to the growth of the biopoin market.

The increasing demand for personalized medicine is expected to further drive the growth of the biopoin market. Personalized medicine tailors treatments based on an individual's unique genetic, environmental, and lifestyle factors. Advances in genetic research have made it possible to identify disease-related genetic markers more accurately, enabling healthcare providers to offer more effective and customized treatments. Biopoins are specifically designed to target molecular markers or mutations in a patient's condition, providing more precise, tailored therapies. This approach improves treatment efficacy, reduces side effects, and shifts away from the traditional one-size-fits-all model. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. As a result, the increasing demand for personalized medicine is expected to drive the growth of the biopoin market.

The key company operating in the biopoin market is Teva Pharmaceutical Industries.

North America was the largest region in the biopoin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biopoin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biopoin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biopoin is a biopharmaceutical product designed to treat anemia, particularly in adults with chronic kidney disease or those undergoing chemotherapy for non-myeloid cancers. It contains epoetin theta, a recombinant version of erythropoietin, which promotes the production of red blood cells. By boosting hemoglobin levels, Biopoin helps reduce anemia-related fatigue and weakness.

The primary uses of biopoin include managing anemia associated with chronic kidney disease, cancer-related anemia, surgical anemia, and more. Anemia in chronic kidney disease (CKD) occurs when the damaged kidneys produce less erythropoietin, a hormone crucial for red blood cell production. This results in lower hemoglobin levels, leading to fatigue and challenges in maintaining adequate oxygen levels in the body. Treatment options often involve erythropoiesis-stimulating agents, iron supplements, and occasionally blood transfusions. Biopoin treatments play a vital role in enhancing the quality of life for CKD patients. The product is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and it is utilized by various patient groups, including adults, the elderly, and children.

The biopoin market research report is one of a series of new reports that provides Biopoin market statistics, including the Biopoin industry's global market size, regional shares, competitors with a Biopoin market share, detailed Biopoin market segments, market trends and opportunities, and any further data you may need to thrive in the Biopoin industry. This Biopoin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biopoin market consists of sales of pre-filled syringes and erythropoiesis-stimulating agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.